2d
Zacks.com on MSNIs it Worth Retaining QIAGEN Stock in Your Portfolio Now?QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...
7d
Zacks Investment Research on MSNQGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal PanelQIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...
7d
Zacks Investment Research on MSNQiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?A month has gone by since the last earnings report for Qiagen (QGEN). Shares have lost about 6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to ...
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.
We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at ...
Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. This marks Qiagen’s second ...
Kepler Capital analyst Maja Pataki maintained a Hold rating on Qiagen (QGEN – Research Report) on February 6 and set a price target of €42.17.
A month has gone by since the last earnings report for Qiagen (QGEN). Shares have lost about 6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...
QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results